Keeler News
Print this Article | Send to Colleague
Keeler News
Keeler USA & Avellino Enter into Distribution Agreement to Sell AvaGen™, The Genetic Eye Test
Keeler, a world leader in ophthalmic diagnostic, digital, surgical, and clinical products is proud to announce our partnership with Avellino Lab USA, Inc. (Avellino).
Avellino Lab USA, Inc. is a global leader in genetic molecular diagnostics at the forefront of precision medicine for eye care. AvaGen is the first genetic test that helps determine a patient’s risk of keratoconus and the presence of TGFBI corneal dystrophies. The test allows for more confident management and treatment for patients with these conditions in order to protect and preserve patient vision. The test examines 75 keratoconus-related genes and more than 2,000 variants of those genes to develop an actionable genetic risk score for keratoconus.
“We are excited to partner with Keeler and provide expanded availability to this one-of-a-kind genetic test that can help earlier detect both keratoconus and certain corneal dystrophies,” says Avellino Global Head of Sales and Marketing Joe Boyd. “With these type of genetic conditions, early detection is key in protecting vision, and this new distribution channel will provide eye care professionals another way to access this groundbreaking test.”
